title: Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP)
abstract: OBJECTIVE
  Our purpose was to evaluate the impact of antepartum administration of corticosteroids on the course of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in pregnancies at 24 to 37 weeks' gestation.
  
  
  METHODS
  This prospective, randomized study was undertaken in 25 antepartum patients with atypical severe preeclampsia expressed as HELLP syndrome. Twelve pregnant women were randomized to receive double-dose dexamethasone (10 mg intravenously every 12 hours) until delivery, and 13 women were randomized to the control arm. Management and delivery decisions for all patients were based on a common protocol, with delivery undertaken for a deteriorating maternal or fetal condition.
  
  
  RESULTS
  In the corticosteroid-treated group the maternal platelet count significantly increased (p = 0.006), whereas lactic dehydrogenase and alanine aminotransferase significantly decreased over time (p = 0.03 and p = 0.005) in comparison to the 13 women who did not receive corticosteroids. Maternal urinary output after entry into the study was significantly increased within hours after steroid administration versus the control group (p = 0.0006). The study entry-to-delivery interval (41 +/- 15 hours) was significantly longer in the group of steroid-treated women (p = 0.0068).
  
  
  CONCLUSIONS
  Stabilization and significant improvement in the laboratory and clinical parameters associated with HELLP syndrome occurred in women who received high-dose antenatal corticosteroids, as measured by maternal platelet count, urinary output, lactic dehydrogenase, alanine aminotransferase, and postponement of delivery. We believe the findings of this investigation permit us to speculate that this therapeutic approach could enhance maternal-fetal care by postponing delivery of some previable fetuses, reduce the need for maternal transfusion of blood products, reduce neonatal morbidity or mortality from multiple systemic effects, and facilitate a safer transfer of the ill mother to a tertiary care site for optimal peripartal care.
authors.affiliation: Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson 39216-4505.
authors.forename: E F
authors.initials: EF
authors.lastname: Magann
authors.forename: D
authors.initials: D
authors.lastname: Bass
authors.forename: S P
authors.initials: SP
authors.lastname: Chauhan
authors.forename: D L
authors.initials: DL
authors.lastname: Sullivan
authors.forename: R W
authors.initials: RW
authors.lastname: Martin
authors.forename: J N
authors.initials: JN
authors.lastname: Martin
mesh_terms: D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000704:Analysis of Variance; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D016002:Discriminant Analysis; D005260:Female; D017359:HELLP Syndrome / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016014:Linear Models; D015999:Multivariate Analysis; D010976:Platelet Count / Q000187:drug effects; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D011446:Prospective Studies
chemical_list: D003907:Dexamethasone; D007770:L-Lactate Dehydrogenase; D000410:Alanine Transaminase